Your browser doesn't support javascript.
loading
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer, Christopher N; Garfinkel, Amanda C; Venturini, Gabriela; Wakimoto, Hiroko; Repetti, Giuliana; Alamo, Lorenzo; Sharma, Arun; Agarwal, Radhika; Ewoldt, Jourdan K; Cloonan, Paige; Letendre, Justin; Lun, Mingyue; Olivotto, Iacopo; Colan, Steve; Ashley, Euan; Jacoby, Daniel; Michels, Michelle; Redwood, Charles S; Watkins, Hugh C; Day, Sharlene M; Staples, James F; Padrón, Raúl; Chopra, Anant; Ho, Carolyn Y; Chen, Christopher S; Pereira, Alexandre C; Seidman, Jonathan G; Seidman, Christine E.
Afiliação
  • Toepfer CN; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Garfinkel AC; Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.
  • Venturini G; Wellcome Centre for Human Genetics (C.N.T., H.C.W.), University of Oxford, UK.
  • Wakimoto H; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Repetti G; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Alamo L; Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor)-University of São Paulo Medical School, Brazil (G.V., A.C.P.).
  • Sharma A; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Agarwal R; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Ewoldt JK; Centro de Biología Estructural, Instituto Venezolano de Investigaciones Cientifìcas (IVIC), Caracas (L.A., R.P.).
  • Cloonan P; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Letendre J; Department of Genetics, Harvard Medical School, Boston, MA (C.N.T., A.C.G., G.V., H.W., G.R., A.S., R.A., A.C.P., J.G.S., C.E.S.).
  • Lun M; Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).
  • Olivotto I; Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).
  • Colan S; Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).
  • Ashley E; Department of Medicine, Division of Genetics (M.L.), Brigham and Women's Hospital, Boston, MA.
  • Jacoby D; Cardiomyopathy Unit and Genetic Unit, Careggi University Hospital, Florence, Italy (I.O.).
  • Michels M; Department of Cardiology, Boston Children's Hospital, MA (S.C.).
  • Redwood CS; Center for Inherited Cardiovascular Disease, Stanford University, CA (E.A.).
  • Watkins HC; Department of Internal Medicine, Section of Cardiovascular Diseases, Yale School of Medicine, New Haven, CT (D.J.).
  • Day SM; Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands (M.M.).
  • Staples JF; Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.
  • Padrón R; Cardiovascular Medicine, Radcliffe Department of Medicine (C.N.T., C.S.R., H.C.W.), University of Oxford, UK.
  • Chopra A; Wellcome Centre for Human Genetics (C.N.T., H.C.W.), University of Oxford, UK.
  • Ho CY; Department of Internal Medicine, University of Michigan, Ann Arbor (S.M.D.).
  • Chen CS; Department of Biology, University of Western Ontario, London, Canada (J.F.S.).
  • Pereira AC; Centro de Biología Estructural, Instituto Venezolano de Investigaciones Cientifìcas (IVIC), Caracas (L.A., R.P.).
  • Seidman JG; Division of Cell Biology and Imaging, Department of Radiology, University of Massachusetts Medical School, Worcester (R.P.).
  • Seidman CE; Department of Biomedical Engineering, Boston University, MA (J.F.E., P.C., J.L., A.C., C.S.C.).
Circulation ; 141(10): 828-842, 2020 03 10.
Article em En | MEDLINE | ID: mdl-31983222
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic variants in sarcomere protein genes that evoke hypercontractility, poor relaxation, and increased energy consumption by the heart and increased patient risks for arrhythmias and heart failure. Recent studies show that pathogenic missense variants in myosin, the molecular motor of the sarcomere, are clustered in residues that participate in dynamic conformational states of sarcomere proteins. We hypothesized that these conformations are essential to adapt contractile output for energy conservation and that pathophysiology of HCM results from destabilization of these conformations. METHODS: We assayed myosin ATP binding to define the proportion of myosins in the super relaxed state (SRX) conformation or the disordered relaxed state (DRX) conformation in healthy rodent and human hearts, at baseline and in response to reduced hemodynamic demands of hibernation or pathogenic HCM variants. To determine the relationships between myosin conformations, sarcomere function, and cell biology, we assessed contractility, relaxation, and cardiomyocyte morphology and metabolism, with and without an allosteric modulator of myosin ATPase activity. We then tested whether the positions of myosin variants of unknown clinical significance that were identified in patients with HCM, predicted functional consequences and associations with heart failure and arrhythmias. RESULTS: Myosins undergo physiological shifts between the SRX conformation that maximizes energy conservation and the DRX conformation that enables cross-bridge formation with greater ATP consumption. Systemic hemodynamic requirements, pharmacological modulators of myosin, and pathogenic myosin missense mutations influenced the proportions of these conformations. Hibernation increased the proportion of myosins in the SRX conformation, whereas pathogenic variants destabilized these and increased the proportion of myosins in the DRX conformation, which enhanced cardiomyocyte contractility, but impaired relaxation and evoked hypertrophic remodeling with increased energetic stress. Using structural locations to stratify variants of unknown clinical significance, we showed that the variants that destabilized myosin conformations were associated with higher rates of heart failure and arrhythmias in patients with HCM. CONCLUSIONS: Myosin conformations establish work-energy equipoise that is essential for life-long cellular homeostasis and heart function. Destabilization of myosin energy-conserving states promotes contractile abnormalities, morphological and metabolic remodeling, and adverse clinical outcomes in patients with HCM. Therapeutic restabilization corrects cellular contractile and metabolic phenotypes and may limit these adverse clinical outcomes in patients with HCM.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcômeros / Cardiomiopatia Hipertrófica / Cadeias Pesadas de Miosina / Mutação de Sentido Incorreto / Miosinas Cardíacas / Miócitos Cardíacos Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcômeros / Cardiomiopatia Hipertrófica / Cadeias Pesadas de Miosina / Mutação de Sentido Incorreto / Miosinas Cardíacas / Miócitos Cardíacos Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article